New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
UP AFTER EARNINGS: VeriFone (PAY), up 8.5%... Primo Water (PRMW), up 8.3%... QIWI (QIWI), up 2.5%. ALSO HIGHER: Oxigene (OXGN), up 128% following results from its Phase 2 clinical trial evaluating Avastin with or without ZYBRESTAT to treat patients with recurrent ovarian cancer... Rite Aid (RAD), up 3% following upgrade at Goldman... EPL Oil & Gas (EPL), up 28.8% after Energy XXI (EXXI) to acquire the company for $2.3B. DOWN AFTER EARNINGS: Express (EXPR), down 13%... Kratos Defense (KTOS), down 10%. ALSO LOWER: Hyperdynamics (HDY), down 59% after U.S. Department of Justice and the SEC to open investigations into the activities of the company... Geron (GERN), down 61% after announcing IND clinical hold affecting trials of imetelstat... Synta Pharmaceuticals (SNTA), down 16.7% after downgraded at Stifel, BMO Capital... FuelCell (FCEL), down 3.6% following downgrade at Cowen... MagnaChip (MX), down 10.7% after announcing it will restate prior financial statements... Northwest Biotherapeutics (NWBO), down 6.8% following downgrade at Oppenheimer.
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
08:39 EDTEXPRExpress December volatility elevated into Q3 and outlook
Subscribe for More Information
November 25, 2014
18:03 EDTQIWIQIWI acquires Money.Mail.Ru
Subscribe for More Information
November 21, 2014
10:50 EDTGERNGeron November volatility at low end of two-year range as shares trend higher
Geron December call option implied volatility is at 86, January is at 88, March is at 78; compared to its 26-week average of 106 according to Track Data, suggesting decreasing price risk.
November 19, 2014
11:42 EDTEXXIEnergy XXI director discloses 10K share purchase at $6.63
Subscribe for More Information
07:04 EDTSNTASynta Pharmaceuticals presents preclinical results from Hsp90 platform
Synta Pharmaceuticals announced that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona. “This poster highlights our ongoing evaluation of multiple candidates from the HDC platform. The preclinical results for our lead candidates not only demonstrate broad activity across several tumor types, but also the ability for HDCs to induce prolonged antitumor effects as compared to well-established cytotoxic agents,” said Weiwen Ying, Vice President, Discovery Chemistry at Synta. “In addition, the platform is not limited to using traditional cytotoxic therapeutics as payloads. A number of commonly used small molecule anticancer agents may also be incorporated, including tyrosine kinase inhibitors, proteosome inhibitors, small molecule immunotherapeutics, and other molecularly targeted agents. By leveraging the preferential retention characteristic of the Hsp90 targeting arm of an HDC in tumors, intratumoral exposure and antitumor potency for a wide array of payloads can be potentially improved." "We are encouraged by the progress the team has achieved to date with candidates arising from the HDC platform and the promise that the platform holds for both internal development and partnerships,” said Anne Whitaker, President and CEO of Synta. “We continue to evaluate options for efficiently advancing candidates from this platform and look forward to providing updates in the future.”
November 17, 2014
16:05 EDTOXGNOXiGENE announces issuance of European patent for OXi4503
Subscribe for More Information
11:06 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 14, 2014
16:21 EDTGERNOn The Fly: Closing Wrap
Subscribe for More Information
12:58 EDTGERNOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTGERNGeron November volatility up on strategic collaboration with Janssen Biotech
Subscribe for More Information
10:00 EDTGERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTEXXIHayman Capital gives quarterly update on stakes
Subscribe for More Information
07:12 EDTGERNGeron upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use